Management of Non-Hodgkin Lymphoma in Adults in Scandinavia, United Kingdom, and the Netherlands: Report from the European School of Oncology Intercity Meeting at Huddinge Hospital, 3rd June, 1988

Authors

  • G. Juliusson Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • A. F. Abrahamsen Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • E. Cavallin-Ståhl Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • A. H. Goldstone Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • T. A. Lister Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • N. I. Nissen Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • K.-H. Robèrt Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands,
  • C. R. J. Singer Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • R. Somers Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • Å. Öst Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
  • G. Gahrton Division of Clinical Haematology and Oncology, Department of Medicine, Karo-Linska Institute at Huddinge Hospital, Lund, Sweden; Department of Pathology, Karolinska Hospital, Lund, Sweden; Department of Oncology, University Hospital, Lund, Sweden; Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway; Department of Haematology, The Finsen Institute, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, University College Hospital, London, England; Department of Medical Oncology, St. Bartholomew's Hospital, London, England; Department of Medicine, The Netherlands Cancer Institute, Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands

DOI:

https://doi.org/10.3109/02841868909111195

Keywords:

Non-Hodgkin lymphoma, staging procedures,, chemotherapy, prognosis, bone marrow transplantation

Abstract

Current treatment strategies in northern Europe of non-Hodgkin lymphoma are presented. High-grade malignant lymphomas have been treated with doxorubicin-containing polychemotherapy in various modes. The advantage of six-drug regimens over CHOP-like therapy is as yet not proven. Patients with the ability to tolerate the calculated dose have good prognosis. High-dose therapy and bone marrow transplantation should be considered in poor-risk patients with lymphoblastic lymphomas in first remission, patients with all high-grade histologies in partial remission after first-line therapy and patients with relapse that are still responsive to therapy. Preliminary results from autologous bone marrow transplantation in follicular lymphoma are also encouraging. Chlorambucil induces multiple remissions in follicular lymphoma, with a median duration of the 1st, 2nd and 3rd remission being the same. The watch and wait strategy seems justified initially in most asymptomatic generalized low-grade malignant lymphomas. Systemic therapy is required in aggressive stage II-IV lymphomas. A meticulous investigation is needed for stage I patients before giving local treatment only. Immune phenotyping is of great value for diagnosis and staging. Liver, but not bone marrow involvement seems to be an adverse prognostic factor. Follicular lymphoma is an example of a dynamic tumour with gradual cellular changes associated with new and more malignant clinical signs.

Downloads

Download data is not yet available.

Downloads

Published

1989-01-01

How to Cite

Juliusson, G. ., Abrahamsen, A. F. ., Cavallin-Ståhl, E. ., Goldstone, A. H. ., Lister, T. A. ., Nissen, N. I., … Gahrton, G. (1989). Management of Non-Hodgkin Lymphoma in Adults in Scandinavia, United Kingdom, and the Netherlands: Report from the European School of Oncology Intercity Meeting at Huddinge Hospital, 3rd June, 1988. Acta Oncologica, 28(1), 135–140. https://doi.org/10.3109/02841868909111195

Issue

Vol. 28 No. 1 (1989): Acta Oncologica

Section

Articles